Ardelyx Soars on Positive Phase 3 Data -- Biotech Movers

Shares of Ardelyx Inc. (ARDX) jumped 41.7% to $7.65 ahead of the market open on Thursday, Oct. 12, after the Fremont, Calif.-based firm unveiled positive results from its second Phase 3 study of tenapanor for irritable bowel syndrome with constipation.

In the news release issued after the market close on Wednesday, Ardelyx president and CEO Mike Raab called the results a "game-changer for patients with IBS-C, their treating physicians and for Ardelyx as a company."

"These results show that tenapanor has significant potential in the market and bolsters our commitment to identify the ideal collaboration partner to help ensure that we reach the most patients possible who would benefit from therapy," Raab added.

Meanwhile, shares of Trevena Inc. (TRVN) were down 15.6% to $2 after the Chesterbrook, Pa.-based company
said it is trimming its workforce by about 30%, or 21 full-time employees, mainly from its research team. As part of the restructuring,  chief scientific officer Michael Lark, Ph.D., will leave the company in mid-December. 

Trevena said it is halting its investment in early-stage research, opting to focus its resources on the potential approval and commercialization of Olinvo (oliceridine injection) in the U.S. The firm said it plans to complete the ongoing Phase 1 study of TRV250 for acute migraine, after which it will evaluate options for further development of the asset, as well as for its series of novel S1P modulators for neuropathic pain.

The company also said its new drug application for Olinvo continues to be on pace for submission to the U.S. Food and Drug Administration this month.

Among the other biotech stock movers was Ophthotech Corp. (OPHT) , up 4.7% to $2
Read the full story and get access to the Real Money Pro trading floor.

There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.

Already a Subscriber? Please login.

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.